Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials.
Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.
An Open-label Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
This is a Phase 2 open-label study to evaluate the efficacy and safety of ibrutinib in combination with bortezomib and dexamethasone for patients with relapsed or relapsed and refractory multiple myeloma.
100 Clinical Results associated with Pharmacyclics Switzerland GmbH
0 Patents (Medical) associated with Pharmacyclics Switzerland GmbH
100 Deals associated with Pharmacyclics Switzerland GmbH
100 Translational Medicine associated with Pharmacyclics Switzerland GmbH